Literature DB >> 16210669

The NHLBI lymphangioleiomyomatosis registry: characteristics of 230 patients at enrollment.

Jay H Ryu1, Joel Moss, Gerald J Beck, Jar-Chi Lee, Kevin K Brown, Jeffrey T Chapman, Geraldine A Finlay, Eric J Olson, Stephen J Ruoss, Janet R Maurer, Thomas A Raffin, Hannah H Peavy, Kevin McCarthy, Angelo Taveira-Dasilva, Francis X McCormack, Nilo A Avila, Rosamma M Decastro, Susan S Jacobs, Mario Stylianou, Barry L Fanburg.   

Abstract

RATIONALE: Pulmonary lymphangioleiomyomatosis is a progressive cystic lung disease that is associated with infiltration of atypical smooth muscle-like cells. Previous descriptions of clinical characteristics of subjects with lymphangioleiomyomatosis have been based on a limited number of patients.
OBJECTIVES: To describe the clinical characteristics of subjects with pulmonary lymphangioleiomyomatosis, both sporadic and tuberous sclerosis-related forms.
METHODS: Over a 3-yr period, from 1998 to 2001, 243 subjects with pulmonary lymphangioleiomyomatosis were enrolled into a national registry; 13 subjects who had already undergone lung transplantation were excluded for the purposes of this report.
MEASUREMENTS AND MAIN RESULTS: All 230 subjects were women, aged 18 to 76 yr (mean +/- SE, 44.5 +/- 0.65 yr). The average age at onset of symptoms was 38.9 +/- 0.73 yr and at diagnosis was 41.0 +/- 0.65 yr. Tuberous sclerosis complex was present in 14.8% of subjects. Pulmonary manifestations, most commonly spontaneous pneumothorax, were the primary events leading to the diagnosis in 86.5% of cases. Nearly 55% of the subjects were being treated with a progesterone derivative. An obstructive pattern on pulmonary function testing was observed in 57.3% of the subjects, whereas 33.9% had normal spirometric results. Women with tuberous sclerosis-related lymphangioleiomyomatosis were younger and had less impaired lung function compared with those with the sporadic form.
CONCLUSIONS: The age range of women afflicted with pulmonary lymphangioleiomyomatosis is broader than previously appreciated and the degree of pulmonary function can be quite variable, with one-third of subjects having normal spirometry at enrollment into this registry.

Entities:  

Mesh:

Year:  2005        PMID: 16210669      PMCID: PMC2662978          DOI: 10.1164/rccm.200409-1298OC

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  38 in total

1.  Importance of adjusting carbon monoxide diffusing capacity (DLCO) and carbon monoxide transfer coefficient (KCO) for alveolar volume.

Authors:  D C Johnson
Journal:  Respir Med       Date:  2000-01       Impact factor: 3.415

Review 2.  Lymphangioleiomyomatosis.

Authors:  J Kelly; J Moss
Journal:  Am J Med Sci       Date:  2001-01       Impact factor: 2.378

3.  Pulmonary lymphangioleiomyomatosis in a man.

Authors:  M C Aubry; J L Myers; J H Ryu; E P Henske; H Logginidou; S M Jalal; H D Tazelaar
Journal:  Am J Respir Crit Care Med       Date:  2000-08       Impact factor: 21.405

4.  Decline in lung function in patients with lymphangioleiomyomatosis treated with or without progesterone.

Authors:  Angelo M Taveira-DaSilva; Mario P Stylianou; Carolyn J Hedin; Olanda Hathaway; Joel Moss
Journal:  Chest       Date:  2004-12       Impact factor: 9.410

5.  American Thoracic Society. Single-breath carbon monoxide diffusing capacity (transfer factor). Recommendations for a standard technique--1995 update.

Authors: 
Journal:  Am J Respir Crit Care Med       Date:  1995-12       Impact factor: 21.405

6.  Mutational and radiographic analysis of pulmonary disease consistent with lymphangioleiomyomatosis and micronodular pneumocyte hyperplasia in women with tuberous sclerosis.

Authors:  D N Franz; A Brody; C Meyer; J Leonard; G Chuck; S Dabora; G Sethuraman; T V Colby; D J Kwiatkowski; F X McCormack
Journal:  Am J Respir Crit Care Med       Date:  2001-08-15       Impact factor: 21.405

7.  Downregulation of estrogen and progesterone receptors in the abnormal smooth muscle cells in pulmonary lymphangioleiomyomatosis following therapy. An immunohistochemical study.

Authors:  K Matsui; K Takeda; Z X Yu; J Valencia; W D Travis; J Moss; V J Ferrans
Journal:  Am J Respir Crit Care Med       Date:  2000-03       Impact factor: 21.405

8.  High frequency of pulmonary lymphangioleiomyomatosis in women with tuberous sclerosis complex.

Authors:  L C Costello; T E Hartman; J H Ryu
Journal:  Mayo Clin Proc       Date:  2000-06       Impact factor: 7.616

9.  Lymphangioleiomyomatosis: abdominopelvic CT and US findings.

Authors:  N A Avila; J A Kelly; S C Chu; A J Dwyer; J Moss
Journal:  Radiology       Date:  2000-07       Impact factor: 11.105

10.  Clinical experience of lymphangioleiomyomatosis in the UK.

Authors:  S R Johnson; A E Tattersfield
Journal:  Thorax       Date:  2000-12       Impact factor: 9.139

View more
  118 in total

1.  A National Heart, Lung, and Blood Institute history and perspective on lymphangioleiomyomatosis.

Authors:  Hannah Peavy; Dorothy Gail; James Kiley; Susan Shurin
Journal:  Lymphat Res Biol       Date:  2010-03       Impact factor: 2.589

2.  Incidence of Pneumothorax in Patients With Lymphangioleiomyomatosis Undergoing Pulmonary Function and Exercise Testing.

Authors:  Angelo M Taveira-DaSilva; Patricia Julien-Williams; Amanda M Jones; Joel Moss
Journal:  Chest       Date:  2016-07       Impact factor: 9.410

Review 3.  Sex-specific lung diseases: effect of oestrogen on cultured cells and in animal models.

Authors:  Bosung Shim; Gustavo Pacheco-Rodriguez; Jiro Kato; Thomas N Darling; Martha Vaughan; Joel Moss
Journal:  Eur Respir Rev       Date:  2013-09-01

4.  A 48-year-old woman with lymphangioleiomyomatosis.

Authors:  Erica Weir; Marsha Cohen
Journal:  CMAJ       Date:  2007-04-24       Impact factor: 8.262

5.  Pneumothorax after air travel in lymphangioleiomyomatosis, idiopathic pulmonary fibrosis, and sarcoidosis.

Authors:  Angelo M Taveira-DaSilva; Dara Burstein; Olanda M Hathaway; Joseph R Fontana; Bernardette R Gochuico; Nilo A Avila; Joel Moss
Journal:  Chest       Date:  2009-03-24       Impact factor: 9.410

6.  Concentration of Serum Vascular Endothelial Growth Factor (VEGF-D) and Its Correlation with Functional and Clinical Parameters in Patients with Lymphangioleiomyomatosis from a Brazilian Reference Center.

Authors:  Alexandre Franco Amaral; Martina Rodrigues de Oliveira; Olívia Meira Dias; Fábio Eiji Arimura; Carolina Salim Gonçalves Freitas; Milena Marques Pagliarelli Acencio; Vanessa Adélia de Alvarenga; Ronaldo Adib Kairalla; Carlos Roberto Ribeiro Carvalho; Bruno Guedes Baldi
Journal:  Lung       Date:  2019-01-08       Impact factor: 2.584

7.  Characterization of lymphangioleiomyomatosis patients with discordance between spirometric and diffusion measurements of pulmonary function.

Authors:  Andrew M Courtwright; Bruno G Baldi; Pranav Kidambi; Ye Cui; Anthony M Lamattina; Julian A Villalba; Shefali Bagwe; Hilary J Goldberg; Ivan O Rosas; Elizabeth Petri Henske; Carlos R R Carvalho; Souheil El-Chemaly
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2018-04-28       Impact factor: 0.670

8.  St. George's Respiratory Questionnaire has longitudinal construct validity in lymphangioleiomyomatosis.

Authors:  Jeffrey J Swigris; Hye-Seung Lee; Marsha Cohen; Yoshikazu Inoue; Joel Moss; Lianne G Singer; Lisa R Young; Francis X McCormack
Journal:  Chest       Date:  2013-06       Impact factor: 9.410

9.  Predictors for clinical trial participation in the rare lung disease lymphangioleiomyomatosis.

Authors:  Brent W Kinder; A C Sherman; L R Young; J T Hagaman; N Oprescu; S Byrnes; Francis X McCormack
Journal:  Respir Med       Date:  2009-12-04       Impact factor: 3.415

10.  Reversible airflow obstruction in lymphangioleiomyomatosis.

Authors:  Angelo M Taveira-DaSilva; Wendy K Steagall; Antoinette Rabel; Olanda Hathaway; Sergio Harari; Roberto Cassandro; Mario Stylianou; Joel Moss
Journal:  Chest       Date:  2009-05-15       Impact factor: 9.410

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.